Assessing Dianthus Therapeutics (DNTH) Valuation Following Strong Revenue Growth and Recent Share Price Momentum [Yahoo! Finance]
Dianthus Therapeutics, Inc. (DNTH)
Company Research
Source: Yahoo! Finance
catching the attention of investors seeking momentum in the biotech sector, especially in light of recent stock moves. See our latest analysis for Dianthus Therapeutics. Dianthus Therapeutics has experienced a sharp rise in momentum lately, with a 1-day share price return of 8% and a 90-day surge of 94.19%. The stock's year-to-date climb stands at 57.03%, and its total shareholder return over the past year has reached 21.84%, signaling renewed optimism as revenue growth accelerates. If biotech's recent energy has you curious, it might be the ideal moment to explore other innovators shaping healthcare. Check out See the full list for free. Yet with shares still trading well below analysts' price targets, the question is whether Dianthus Therapeutics remains undervalued and presents a fresh buying opportunity, or if the recent rally has already priced in future growth. Price-to-Book Ratio of 2.6x: Is it justified? Dianthus Therapeutics currently trades at a price-to-book rat
Show less
Read more
Impact Snapshot
Event Time:
DNTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNTH alerts
High impacting Dianthus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DNTH
News
- Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare ConferenceGlobeNewswire
- Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by analysts at HC Wainwright from $40.00 to $47.00. They now have a "buy" rating on the stock.MarketBeat
- Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by analysts at Wedbush from $44.00 to $46.00. They now have an "outperform" rating on the stock.MarketBeat
- Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial ResultsGlobeNewswire
- Dianthus Therapeutics to Participate in Four Investor Conferences During NovemberGlobeNewswire
DNTH
Earnings
- 11/5/25 - Miss
DNTH
Sec Filings
- 12/5/25 - Form 4
- 12/4/25 - Form 144
- 11/25/25 - Form SCHEDULE
- DNTH's page on the SEC website